Abstract
Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.
| Original language | English (US) |
|---|---|
| Pages (from-to) | S1-S9 |
| Journal | American Journal of Cardiology |
| Volume | 116 |
| DOIs | |
| State | Published - Oct 15 2015 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure. / Wolinsky, David; Hendel, Robert; Cerqueira, Manuel; Gold, Michael; Narula, Jagat; Singh, Jagmeet; Shaw, Leslee; Thomas, Gregory; Wazni, Oussama; Farnum, Carolyn.
In: American Journal of Cardiology, Vol. 116, 15.10.2015, p. S1-S9.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients with Heart Failure
AU - Wolinsky, David
AU - Hendel, Robert
AU - Cerqueira, Manuel
AU - Gold, Michael
AU - Narula, Jagat
AU - Singh, Jagmeet
AU - Shaw, Leslee
AU - Thomas, Gregory
AU - Wazni, Oussama
AU - Farnum, Carolyn
PY - 2015/10/15
Y1 - 2015/10/15
N2 - Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.
AB - Despite advances in evidence-based treatments, the morbidity and mortality of congestive heart failure remain exceedingly high. In addition, the costs associated with recurrent hospitalizations and advanced therapies, such as implantable cardiac defibrillators (ICDs), left ventricular assist devices, and heart transplantation, place a substantial financial burden on the health care system. The present criteria for risk stratification in patients with heart failure are inadequate and often prevent the allocation of appropriate treatment. Patients who have received ICDs as primary prevention for sudden cardiac death often receive no device therapy in their lifetime, whereas other patients with left ventricular dysfunction die suddenly without meeting criteria for ICD implantation.
UR - http://www.scopus.com/inward/record.url?scp=84944743128&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84944743128&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2015.09.014
DO - 10.1016/j.amjcard.2015.09.014
M3 - Article
VL - 116
SP - S1-S9
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
ER -